Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial - El-Khoueiry, A B; Sangro, B; Yau, T (Lancet, 2017)
. doi:10.1016/S0140-6736(17)31046-2